EACS2023: 353 Final results of VICDOR: EffectiVeness of SwItChing to DOR-based antiretroviral therapy under real-world conditions in Germany J. Rockstroh , C. Wyen , M. Sabranski , C. Jonsson-Oldenbüttel , J. Bogner , H. Knechten , S. Esser , N. Qurishi , S. Schellberg , I. Kolobova , J.-P. Pelz , Y. O Whiteside , B. Tadese University Hospital Bonn, Bonn, Germany, Praxis am Ebertplatz, Cologne, Germany, ICH Study Center, Hamburg, Germany, MVZ München am Goetheplatz, Munich, Germany, University Hospital Munich, Medizinische Klinik und Poliklinik IV, Munich, Germany, Medical Center for HIV and Hepatitis, Laboratory Dr. Knechten, Aachen, Germany, University Hospital Essen, Essen, Germany, Gemeinschaftspraxis Gotenring, Cologne, Germany, Novopraxis Berlin GbR, Berlin, Germany, Merck & Co., Inc., Rahway, United States, MSD Sharp & Dohme GmbH, Munich, Germany General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: The NNRTI doravirine (DOR), combined with other antiretrovirals, is effective and well-tolerated in treating HIV-1 infections. VICDOR characterized the use, effectiveness, and impact on body weight and lipids of DOR-based antiretroviral therapy (ART) in a virologically suppressed switch population. Method: VICDOR was a multicenter, retrospective chart review study in Germany of virologically suppressed adult people with HIV-1 (PWH) who switched to DOR-based ART between January 2019 and June 2021. Demographic, clinical, and laboratory data were collected up to 15 months after switch. Results: Of the 193 PWH included, the median age was 49 years (range=21-78 years), 85.0% were male, 23.8% were obese (BMI ≥30kg/m ), and 80.8% had ≥1 comorbidities. 84.5% switched to DOR/3TC/TDF, and 15.5% switched to another DORbased regimen. Most common reason for switch was to improve tolerability regarding weight gain (37.3%). Prior ARTs were INSTIs (62.7%), NNRTIs (24.9%) and PIs (10.9%); 58.5% were on TAF-containing regimens. Of the 161 individuals who remained on DOR-treatment and had HIV-1 RNA results, 99.4% remained virologically suppressed after 12 months (except n=1 with viral loads of 50-200 copies/ml at month 12 and following visit). No virologic failures occurred. Of those PWH with data for baseline, 6 and 12 months, median low-density lipoprotein-cholesterol (LDL‑C) change was ‑7.10mg/dl (IQR=31; n=89), and those who switched to DOR/3TC/TDF had a median body weight change of -0.85kg (IQR=6; n=50) between switch and month 12. Among patients who switched to DOR/3TC/TDF to improve tolerability regarding weight gain, median weight change was -2.00kg (IQR=4; n=23) after 12 months. Among patients who switched from TAF-containing regimens to DOR/3TC/TDF, median weight change was -1.00kg (IQR=6.90; n=30) after 12 months. Table 1: Demographics Age [years] Median (range) Age at the time of switch 49 (21-78) Gender at birth n (%) Male 164 (84.97) Female 29 (15.03) Body weight [kg] Median (range) Body weight at the time of switch 85.00 (42.90-137.00) BMI [kg/m ] (categorical) n (%) Underweight (BMI <18.5) 2 (1.04) Normal weight (BMI ≥18.5 to <25) 57 (29.53) Overweight (BMI ≥25 to <30) 69 (35.75) Obese Class 1 (BMI ≥30 to <35) 35 (18.13) Obese Class 2 (BMI ≥35 to <40) 7 (3.63) Obese Class 3 (BMI ≥40) 4 (2.07) Missing 19 (9.84) Comorbidities n (%) Yes 156 (80.83) No 37 (19.17) Most frequent comorbidities n (%) Arterial hypertension 59 (30.57) Psychiatric disorder 43 (22.28) Disorder of lipid metabolism 35 (18.13) Bone and bone metabolism disorder 30 (15.54) Cardiac, cardiovascular, or cerebrovascular disorder28 (14.51) Conclusions: The data suggest that DOR-based ART is effective in maintaining virological suppression without evidence of ART-related weight increase in a switch population of PWH with a high prevalence of comorbidities. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 3 4 5 6 7 8 9 10 11 10 10 1 2 3 4 5 6 7 8 9 10 11 2 2 106 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=